Overview
This entry, formerly listed in Orphanet as 'Unclassified overlapping connective tissue disease' (Orphanet code 251316), is now considered an obsolete classification. It was used to describe a group of conditions where a person showed features of more than one connective tissue disease at the same time, but did not fit neatly into any single recognized diagnosis. Connective tissue diseases affect the proteins and structures that hold the body together — including joints, skin, muscles, blood vessels, and internal organs. People placed in this category often had symptoms overlapping several conditions such as lupus (SLE), rheumatoid arthritis, Sjögren's syndrome, systemic sclerosis (scleroderma), and polymyositis or dermatomyositis. Common symptoms included joint pain and swelling, fatigue, skin changes, dry eyes or mouth, muscle weakness, and sometimes involvement of the lungs, kidneys, or heart. Because this classification is now obsolete, patients who were previously given this label are typically re-evaluated and reclassified into more specific diagnoses, such as Mixed Connective Tissue Disease (MCTD) or Undifferentiated Connective Tissue Disease (UCTD). Treatment was and continues to be tailored to the specific symptoms present, often involving anti-inflammatory and immune-suppressing medications. If you carry this older diagnosis, speaking with a rheumatologist about updated classification is strongly recommended.
Key symptoms:
Joint pain and swellingPersistent fatigue and low energySkin rashes or thickeningDry eyes and dry mouthMuscle weaknessRaynaud's phenomenon (fingers turning white or blue in the cold)Shortness of breathDifficulty swallowingSwollen lymph nodesFever without a clear causeHair lossSensitivity to sunlightNumbness or tingling in the hands or feet
Multifactorial
Caused by a mix of several genes and environmental factors
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
2 eventsCHU de Quebec-Universite Laval — NA
Hospital for Special Surgery, New York
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for OBSOLETE: Unclassified overlapping connective tissue disease.
2 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Specialists
View all specialists →No specialists are currently listed for OBSOLETE: Unclassified overlapping connective tissue disease.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to OBSOLETE: Unclassified overlapping connective tissue disease.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Unclassified overlapping connective tissue disease.
Start the conversation →Latest news about OBSOLETE: Unclassified overlapping connective tissue disease
No recent news articles for OBSOLETE: Unclassified overlapping connective tissue disease.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Is my diagnosis still considered 'unclassified overlapping connective tissue disease,' or can it now be reclassified into a more specific condition?,Which of my organs are currently affected, and how will we monitor them over time?,What medications do you recommend, and what are the main side effects I should watch for?,How will I know if I am having a flare, and what should I do when one happens?,Are there lifestyle changes — such as diet, exercise, or sun protection — that could help manage my symptoms?,Should other family members be tested or monitored for similar conditions?,Are there any clinical trials or new treatments I should know about?
Common questions about OBSOLETE: Unclassified overlapping connective tissue disease
What is OBSOLETE: Unclassified overlapping connective tissue disease?
This entry, formerly listed in Orphanet as 'Unclassified overlapping connective tissue disease' (Orphanet code 251316), is now considered an obsolete classification. It was used to describe a group of conditions where a person showed features of more than one connective tissue disease at the same time, but did not fit neatly into any single recognized diagnosis. Connective tissue diseases affect the proteins and structures that hold the body together — including joints, skin, muscles, blood vessels, and internal organs. People placed in this category often had symptoms overlapping several con
How is OBSOLETE: Unclassified overlapping connective tissue disease inherited?
OBSOLETE: Unclassified overlapping connective tissue disease follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Are there clinical trials for OBSOLETE: Unclassified overlapping connective tissue disease?
Yes — 2 recruiting clinical trials are currently listed for OBSOLETE: Unclassified overlapping connective tissue disease on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.